Biosciences investing resistant – but not immune – to global markets’ illnesses

November 25, 2008 | Analyst Insight

Even in a recession, people get sick and need treatment, which is why biotech and pharmaceutical stocks have been seen as a relatively safe haven during the global financial crisis; life sciences...

Related companies	Sol-Gel Technologies, Bain Capital, Venrock Associates, Jerusalem Venture Partners (JVP), DSM Venturing, Johnson & Johnson Development, Novartis, Affymetrix, BP, Battery Ventures, Mascoma, U.S. Department of Energy (DOE), Solix BioSystems, Tengion, Panomics, Medica Venture Partners, 5AM Ventures, Bay City Capital, Bio*One Capital, Qteros, Soros Fund Management

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Interested in Learning More?

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978